153 results
Page 3 of 8
8-K
EX-99.1
rxewgxz0p qj8e
6 Mar 20
Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus
12:00pm
8-K
EX-99.1
izc7my6
27 Feb 20
Regulation FD Disclosure
12:00pm
8-K
EX-99.1
0e4yznmvl
13 Feb 20
Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin
4:05pm
POS AM
oynps7a
17 Oct 19
Prospectus update (post-effective amendment)
5:23pm
POS AM
40eccajeg
20 Sep 19
Prospectus update (post-effective amendment)
4:35pm
8-K
EX-10.1
zf8hxgano9m097fe
22 Jul 19
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
z4dqgwe a4x
22 Jul 19
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
jgaz3ha ae2o6j
16 May 19
Regulation FD Disclosure
10:15am
8-K
EX-3.1
s33fawufracgp48ph
10 May 19
Entry into a Material Definitive Agreement
7:32am
424B5
5v4jwjl7mh8whs3mi
10 May 19
Prospectus supplement for primary offering
7:31am
8-K
EX-99.1
fh2ka93n
31 Jan 19
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
5g8kzg8
17 Dec 18
Regulation FD Disclosure
7:05am
8-K
EX-3.1
i8i23x94ev0uh
9 Oct 18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
6:52am
8-K
EX-10.1
15jm5x0d evn
9 Oct 18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
6:52am
8-K
EX-99.1
7vtwb6z4qyp til9b
9 Oct 18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
6:52am
424B5
nn30wmg56ziw
9 Oct 18
Prospectus supplement for primary offering
6:51am
8-K
EX-99.1
omffc0fpgbuvqauar
29 Jun 18
Innovation Pharmaceuticals Announces $7 million Milestone
2:10pm
8-K
EX-10.1
idsasva4dv4mvt653a
29 Jun 18
Innovation Pharmaceuticals Announces $7 million Milestone
2:10pm